Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02987257 · ClinicalTrials.gov registry record · Phase 3
NATIENS: Optimal Management and Mechanisms of SJS/TEN
A Phase 3 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT02987257 is a Phase 3 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT02987257, a Phase 3 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of supportive care deemed to be the current standard of care. We will leverage the opportunity of this controlled design to collect multiples samples with an aim to discover new genetic and biological markers for prevention and early diagnosis and define cellular and molecular mechanisms to facilitate discovery of promising treatment strategies. This study has been preceded by a planning phase to ensure testing and development of harmonized supportive care infrastructure and operating procedures across sites.
Interventions
- DRUG Harmonized supportive care
- DRUG Etanercept 50 mg sc day 1 and day 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-03-21 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02987257
The ClinicalTrials.gov registry entry for NCT02987257 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Harmonized supportive care is the first listed.
NCT02987257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02987257 about?
NCT02987257 is a clinical study titled "NATIENS: Optimal Management and Mechanisms of SJS/TEN". The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of supportive care deemed to be the current standard of care. We will leverage t...
What is the current status of trial NCT02987257?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2023-03-21. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT02987257?
The interventions under investigation include: Harmonized supportive care (DRUG), Etanercept 50 mg sc day 1 and day 4 (DRUG).
Who is sponsoring clinical trial NCT02987257?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.